Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mesothelioma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Mesothelioma. Displaying page 3 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2012-005834-12 Sponsor Protocol Number: NVALT19 Start Date*: 2013-07-09
    Sponsor Name:Stichting NVALT studies
    Full Title: Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label pha...
    Medical condition: Patients with histologically or cytologically proven malignant mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002180-25 Sponsor Protocol Number: ETOP_13-18 Start Date*: 2019-10-16
    Sponsor Name:European Thoracic Oncology Platform (ETOP)
    Full Title: A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignan...
    Medical condition: advanced malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003524-21 Sponsor Protocol Number: D4880C00003 Start Date*: 2013-11-04
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
    Medical condition: unresectable pleural or peritoneal malignant mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10034670 Peritoneal mesothelioma malignant localised LLT
    18.0 100000004864 10035606 Pleural mesothelioma malignant localised LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) IT (Trial now transitioned) DK (Completed) NL (Ongoing) ES (Completed) FR (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005993-39 Sponsor Protocol Number: IPR/16 Start Date*: 2007-04-26
    Sponsor Name:MOLMED
    Full Title: NGR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than on...
    Medical condition: patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035605 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003111-35 Sponsor Protocol Number: 22864 Start Date*: 2017-03-06
    Sponsor Name:University of Southampton
    Full Title: CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma
    Medical condition: Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-002574-63 Sponsor Protocol Number: 07-058 Start Date*: 2007-07-27
    Sponsor Name:CHU de Caen
    Full Title: Essai randomisé de phase 2-3 testant l’association Pemetrexed-Cisplatine avec ou sans bevacizumab à 15 mg/kg, dans le mésothéliome malin de la plèvre (MPM).
    Medical condition: pleural mesothelioma malignant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000617-67 Sponsor Protocol Number: IRFMN-MPM-7109 Start Date*: 2018-07-03
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase II study to investigate the activity and safety of anti-PD-L1 antibody (Durvalumab) In ADvancEd pretreated malignant pleural Mesothelioma - DIADEM Study
    Medical condition: Advanced malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001774-41 Sponsor Protocol Number: MM04 Start Date*: 2018-04-23
    Sponsor Name:Amphera B.V.
    Full Title: A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemoth...
    Medical condition: Pleural malignant mesothelioma.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001443-63 Sponsor Protocol Number: 01062 Start Date*: 2006-07-10
    Sponsor Name:European Lung Cancer Working Party
    Full Title: A phase II study assessing the activity of valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma.
    Medical condition: This is a prospective phase II study investigating well-known antimetabolite (doxorubicin) and antiepileptic (valproate) drugs, in combination, for the treatment of refractory or recurrent malignan...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023614-31 Sponsor Protocol Number: IPR25 Start Date*: 2011-03-09
    Sponsor Name:MOLMED
    Full Title: NGR019: Randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment in advanced malignant pleural mesothelioma (MPM)
    Medical condition: Advanced MPM patients with non-progressive disease after six cycles of a first-line, pemetrexed-based regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035605 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004489-85 Sponsor Protocol Number: MORAb-009-201 Start Date*: 2015-11-03
    Sponsor Name:Morphotek Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma
    Medical condition: Advanced pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002062-31 Sponsor Protocol Number: ETOP9-15PROMISE-meso Start Date*: 2017-05-12
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma
    Medical condition: Advanced Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004984-35 Sponsor Protocol Number: EZH-501 Start Date*: 2016-08-03
    Sponsor Name:Epizyme, Inc.
    Full Title: Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
    Medical condition: Subjects will receive tazemetostat as dictated in their antecedent study.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027414 Mesotheliomas malignant and unspecified HLT
    19.1 100000004850 10027404 Mesomelia LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007284 Carcinoma LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027408 Mesothelioma malignant advanced LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026667 Malignant peripheral nerve sheath tumor LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073335 Rhabdoid tumor LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064886 Renal medullary carcinoma LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073134 Extraskeletal myxoid chondrosarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062474 Mesothelioma malignant localized LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074121 Rhabdoid tumor of the kidney LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027411 Mesothelioma malignant recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016879-29 Sponsor Protocol Number: IPR/22 Start Date*: 2010-01-25
    Sponsor Name:MOLMED
    Full Title: NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma...
    Medical condition: Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexed
    Disease: Version SOC Term Classification Code Term Level
    12.1 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) IE (Completed) GB (Completed) NL (Completed) BE (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001859-43 Sponsor Protocol Number: CA209-743 Start Date*: 2016-11-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
    Medical condition: Untreated unresectable Pleural Mesothelioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) BE (Completed) DE (Completed) FR (Completed) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001599-31 Sponsor Protocol Number: N16INM Start Date*: 2016-08-25
    Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004902-67 Sponsor Protocol Number: GECP20/09 Start Date*: 2021-08-30
    Sponsor Name:Fundación GECP
    Full Title: A phase II single arm clinical trial assessing the efficacy and safety of BIntrafusp alfa (M7824) in previously treated advanced malignant pleural MESothelioma (BIMES).
    Medical condition: Advanced malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005448-18 Sponsor Protocol Number: MORAb-009-003 Start Date*: 2009-06-04
    Sponsor Name:Morphotek, Inc.
    Full Title: An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
    Medical condition: Advanced pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005331-78 Sponsor Protocol Number: ACT16849 Start Date*: 2022-09-06
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa...
    Medical condition: Pleural mesothelioma Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005605-27 Sponsor Protocol Number: TNG908-C101 Start Date*: 2022-09-07
    Sponsor Name:Tango Therapeutics, Inc.
    Full Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
    Medical condition: Phase 1: • Locally advanced or metastatic MTAP-deleted solid tumors (with the exception of gliomas) Phase 2: • Arm 1: Locally advanced or metastatic MTAP-deleted squamous and nonsquamous NSCLC ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    24.0 100000004864 10085300 Squamous non-small cell lung cancer LLT
    21.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    21.0 100000004864 10027409 Mesothelioma malignant localised LLT
    21.1 100000004864 10026667 Malignant peripheral nerve sheath tumor LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 18:33:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA